GENEMEDICS APP

GENEMEDICS NUTRITION

Ipamorelin

Author: Dr. George Shanlikian, M.D.  |   Last Updated: November 25th, 2024

Share This Page

Book a Free Consultation

Overall Health Benefits of Kisspeptin

Kisspeptin benefits include regulating reproductive hormone release, enhancing fertility, and potentially improving sexual behavior by influencing the hypothalamic-pituitary-gonadal axis. Additionally, it may play a role in energy balance and puberty onset.

  • Increases testosterone levels [1-5]
  • Lowers the risk of heart disease [6-11]
  • Boosts immunity [12-14]
  • Helps lose weight [15-17]
  • Prevents wrinkles and other signs of skin aging [18]
  • Prevents cancer [19-26]
  • Boosts brain power [27-29]
  • Treats fertility disorders [30-35]

Overall Health Benefits of Ipamorelin

Ipamorelin benefits include building lean muscle mass, maintaining healthy bones, improving digestive health, supporting heart health, improving blood sugar levels, strengthening the immune system, preventing cognitive decline, enhancing sex drive and sexual function, promoting tissue regeneration, and improving sleep quality.

  • Builds lean muscle mass [1-28]
  • Maintains healthy bones [29-36]
  • Improves digestive health [37-46]
  • Maintains a healthy heart [47-61]
  • Improves blood sugar levels [62-72]
  • Strengthens the immune system [73-111]
  • Prevents cognitive decline [112-148]
  • Improves sex drive and sexual function [149-183]
  • Enhances tissue regeneration [182-203]
  • Improves sleep quality [204-224]

Key Takeaways of Ipamorelin

  • Muscle Growth and Maintenance: Ipamorelin is highly effective in promoting the growth of lean muscle mass, making it a popular choice for athletes and bodybuilders.
  • Bone Health: It plays a crucial role in maintaining healthy bones, potentially reducing the risk of osteoporosis and other bone-related conditions.
  • Metabolic and Digestive Benefits: Ipamorelin improves digestive health and helps regulate blood sugar levels, contributing to overall metabolic well-being.
  • Enhanced Recovery and Regeneration: The peptide enhances tissue regeneration, aiding in faster recovery from injuries and overall cellular repair.
  • General Health Improvements: Ipamorelin strengthens the immune system, supports heart health, improves sleep quality, and may prevent cognitive decline, offering a wide range of health benefits.

What is Ipamorelin?

Ipamorelin is considered a growth hormone releasing peptide (GHRP) or growth hormone secretagogue. As a pentapeptide (composed of five amino acids), it has the capacity to mimic the bodyā€™s natural release of growth hormone and ghrelin (the hunger hormone). Because this peptide does not affect the release of other hormones in the body such as acetylcholine, aldosterone, cortisol, and prolactin, it has virtually no negative side effects. Therefore, it is considered one of the safest and most effective forms of growth hormone replacement therapy, widely used to fight the effects of aging, manage certain diseases, enhance sports performance, and balance growth hormone deficiency. Furthermore, most medical professionals prescribe ipamorelin more than other therapies because it can help optimize human growth hormone for a longer period of time, thus having a more potent effect.

How Ipamorelin Works

After ipamorelin injection, a selective pulse is sent to the pituitary gland, which in turn releases growth hormone within the body. This causes cells to move toward the muscles to support growth and development while preventing any bone or cartilage deformities. In addition, ipamorelin increases cell synthesis, insulin levels, and ghrelin levels. All of these vital functions work to promote fat loss and increase muscle mass and strength.

Chemical Structure of Ipamorelin

Research on Ipamorelin

A. Builds Lean Muscle Mass

Lean Muscle vs Bulk Muscle What's the Difference

Getting a higher percentage of lean muscle mass while reducing body fat is the most pronounced reason why bodybuilders, athletes, and even amateurs opt for ipamorelin injections. Studies show that ipamorelin has potent muscle-building properties that can help those who want to improve their body composition:

  1. Studies show that ipamorelin boosts the levels of growth hormone (GH), a process that is vital in muscle growth and development. [1-8]
  2. By increasing GH levels, ipamorelin helps enhance muscle synthesis. [1-17]
  3. As a growth hormone releasing peptide, ipamorelin promotes muscle growth and inhibits muscle wasting. [18-19]
  4. In a severely emaciated anorexia nervosa patient, one-year intranasal application of growth hormone-releasing peptide improved muscle mass and strength. [20]
  5. By increasing ghrelin levels, ipamorelin improves muscle mass by increasing food intake. [21-23]
  6. Growth hormone-releasing peptide administration increases muscle mass by promoting muscle regeneration and increasing the levels of collagen. [24-27]
  7. In rats, ipamorelin administration counteracted muscle wasting induced by glucocorticoid injections. [28]

B. Maintains Healthy Bones

Healthy Bones (1)

Aside from achieving lean muscle mass, ipamorelin administration can also help maintain a healthy skeletal frame and prevent various bone disorders. Studies assessing the beneficial effects of ipamorelin on bone health have shown positive results:

  1. In GH-deficient children, administration of growth hormone-releasing peptides such as ipamorelin increased bone growth velocity. [29-33]
  2. In rats, ipamorelin administration induced longitudinal bone growth. [34]
  3. In adult female rats, ipamorelin administration increased bone mineral content without any side effects or toxicities. [35]
  4. A study reported that ipamorelinā€™s ability to stimulate the release of growth hormone can help in bone formation and growth. [36]

C. Improves Digestive Health

Gut Health How to Protect Your Digestive System

Ipamorelin also plays an integral role in maintaining digestive system health. Studies show that growth hormone-releasing peptides such as ipamorelin help improve gastrointestinal function:

  1. Growth hormone-releasing peptide improves digestive health by protecting against various types of ulcers. [37]
  2. In humans, ipamorelin administration improves gastric motility (contractions of gastric smooth muscle) by increasing the levels of ghrelin. [38]
  3. In a severely emaciated anorexia nervosa patient, one-year intranasal application of growth hormone-releasing peptide improved digestive tract dysfunction as evidenced by an increase in food intake and body weight. [39]
  4. In patients who had undergone major abdominal surgery, ipamorelin administration improved upper and lower gastrointestinal tract function. [40]
  5. In rats, ipamorelin administration boosted ghrelin levels, which in turn improved gastrointestinal function. [41-43]
  6. In a rodent model of postoperative ileus (malfunctioning of intestinal motility after abdominal surgery), ipamorelin administration accelerated gastric emptying, which is suggestive of improved gastrointestinal function. [44-45]
  7. In rats, ipamorelin administration increased fecal pellet output following abdominal surgery. [46]

D. Maintains a Healthy Heart

Recent human clinical trials and animal studies show that ipamorelin and other growth hormone- releasing peptides have cardioprotective effects that can help combat various heart diseases:

  1. In patients with heart disease, the administration of growth hormone-releasing peptide improved cardiac output and ventricular mechanical work. [47]
  2. In patients with coronary artery disease undergoing bypass surgery, the administration of growth hormone-releasing peptide increased left ventricular ejection fraction. [48]
  3. In human subjects, the administration of growth hormone-releasing peptide helped protect against heart damage induced by lack of oxygen. [49]
  4. In healthy volunteers, acute intravenous administration of growth hormone-releasing peptide induced a clear and prompt increase in left ventricular ejection fraction. [50-51]
  5. In patients with heart failure, ipamorelin administration increased heart muscle contractions by boosting the levels of IGF-1. [52-54]
  6. In rats, the administration of growth hormone releasing peptide protected against heart injury caused by lack of oxygen. [55]
  7. In rats subjected to experimental myocardial infarction, the administration of growth hormone releasing peptide increased blood volume pumped by the left ventricle of the heart. [56]
  8. In rats, growth hormone-releasing peptide administration increased the strength of muscular contractions of the heart. [57]
  9. In rats, growth hormone-releasing peptide administration prevented heart failure by protecting against radical damage. [58]
  10. In hamsters with dilated cardiomyopathy, 4-week treatment with growth hormone releasing peptide attenuated left ventricular dysfunction and dilation. [59]
  11. In dogs with decreased blood supply to the heart, growth hormone releasing peptide administration prevented death by increasing heart wall thickness, which is suggestive of improved blood circulation. [60]
  12. In pigs, growth hormone releasing peptide administration exhibited antioxidant effects, which in turn reduced damage to the heart muscle. [61]

E. Improves Blood Sugar Levels

Ipamorelin also has potent blood sugar-lowering effects which can help prevent diabetes and other fatal medical conditions associated with chronic elevation of blood sugar levels. Strong scientific evidence supports this beneficial effect:

  1. In diabetic patients, the administration of growth hormone-releasing peptide improved blood sugar levels by increasing GH secretion. [62]
  2. By boosting GH levels, ipamorelin can help lower oneā€™s risk of diabetes. [63]
  3. In diabetic rats, ipamorelin administration stimulated the release of insulin, a hormone that lowers blood sugar levels. [64-65]
  4. In diabetic rats, ipamorelin administration lowered blood sugar levels by increasing IGF-1 production. [66]
  5. The intravenous injection of human growth hormone releasing peptide in rats increased the blood levels of insulin. [67]
  6. In diabetic rats, pretreatment with synthetic growth hormone releasing peptide improved insulin secretion and insulin reserves. [68-72]

F. Strengthens the Immune System

There is increasing evidence that ipamorelin may help boost immune function through various important mechanisms:

  1. The administration of growth hormone releasing peptides may help improve the quality of life of cancer patients by correcting nutritional and metabolic states. [73]
  2. In patients with growth hormone deficiency, boosting GH levels through growth hormone releasing peptide administration increased the levels of white blood cells, T cells, and B cells of the immune system. [74-75]
  3. In rats, the administration of growth hormone-releasing peptides such as ipamorelin countered inflammation via the AKT1-activated pathway and reduced programmed cell death (apoptosis) while combating oxidative stress. [76-77]
  4. In animal models, growth hormone releasing peptide administration protected against multiple sclerosis, nerve damage, and brain diseases. [78-81]
  5. In mice, growth hormone releasing peptide administration enhanced antibody titers against various harmful microorganisms. [82]
  6. As a growth hormone releasing peptide, ipamorelin helps strengthen the immune system by boosting GH levels. [83-95]
  7. As a growth hormone stimulant, ipamorelin enhances immune function by stimulating T and B cell proliferation and immunoglobulin synthesis and aiding in the maturation of stem cells and modulation of the inflammatory response. [96]
  8. By increasing GH levels, ipamorelin improves the functional activity of circulating phagocyte cells (cells that engulf foreign bodies). [97]
  9. Ipamorelin can also improve the cytotoxic activity mediated by natural killer cells. [98-100]
  10. By boosting GH levels, ipamorelin can increase the production of various immune system cells such as IL-1Ī², TNF-Ī±, IL-6, and cytokines. [101-102]
  11. Growth hormone secretagogues such as ipamorelin enhance the development of the thymus, a gland that produces T cells for the immune system. [103-110]
  12. The administration of growth hormone secretagogues increased tumor resistance in mice. [111]

G. Prevents Cognitive Decline

By restoring growth hormone to healthy levels, ipamorelin together with other growth hormone- releasing peptides can help prevent age-related decline in cognitive function as well as those caused by certain medical conditions:

  1. In patients with cognitive impairment, the administration of growth hormone secretagogues such as ipamorelin improved age-related decline in cognitive function. [112]
  2. In older adults, the administration of growth hormone secretagogues improved short-term memory and active problem-solving skills. [113]
  3. In healthy older men and women, the administration of growth hormone secretagogues improved cognitive function. [114]
  4. In healthy older adults, the administration of growth hormone secretagogues prevented cognitive decline associated with aging and Alzheimer’s disease. [115]
  5. In adults with mild cognitive impairment and older adults with normal cognitive function, the administration of growth hormone secretagogues improved cognitive function by increasing the levels of brain chemicals such as gamma-Aminobutyric acid and N-acetyl-aspartyl-glutamate. [116]
  6. By boosting ghrelin levels, ipamorelin helps protect brain cells against programmed cell death, thereby preventing cognitive decline. [117-122]
  7. Ipamorelin administration can help prevent Parkinsonā€™s disease by boosting ghrelin levels, which in turn prevents the loss of dopamine, a brain chemical that plays a major role in reward-motivated behavior. [123-130]
  8. The administration of growth hormone secretagogues boosts IGF-1 levels, which in turn activates intracellular pathways involved in the protection of nerve cells in the brain. [131-148]

H. Improves Sex Drive and Sexual Function

As a growth hormone releasing peptide, ipamorelin can indirectly increase libido and improve sexual function by boosting the levels of GH and IGF-1:

  1. Compelling evidence suggests that growth hormone deficiency is strongly linked with low libido and erectile dysfunction, suggesting that boosting GH levels through ipamorelin supplementation may have beneficial effects on libido. [149-156]
  2. There is increasing evidence that IGF-1 deficiency is strongly linked with low libido and erectile dysfunction, suggesting that ipamorelin supplementation may help improve sexual drive and function. [157-163]
  3. In age-advanced men, growth hormone releasing peptide supplementation significantly improved libido and general well-being. [164]
  4. By increasing GH and IGF-1 levels, ipamorelin indirectly improves sexual function by increasing the levels of nitric oxide, a molecule naturally produced in the body that stimulates harder and longer penile erections. [165-173]
  5. Aside from GH and IGF-1 levels, ipamorelin administration also boosts testosterone and estrogen levels, which are necessary for the regulation of sexual thoughts, desire, and sexual function. [174-175]
  6. Studies show that growth hormone-releasing peptides play an integral role in penile erection and sexual arousal. [176-183]

I. Enhances Tissue Regeneration

Growth hormone-releasing peptides such as ipamorelin can help repair damaged tissues caused by a sports injury or physical trauma. There is strong scientific evidence supporting the regenerative properties of ipamorelin:

  1. Ipamorelin and other peptides can be a therapeutic option for cartilage repair and regeneration. [184-185]
  2. Peptides can enhance tissue regeneration by improving collagen synthesis and providing structural and biochemical support to the surrounding cells of the injured area. [186]
  3. Peptides can also speed up the wound healing process by increasing the production of collagen. [187-189]
  4. Peptides can accelerate the healing of various cartilage defects. [190-193]
  5. By recruiting certain cells needed for the repair of damaged tissue, peptides reduce healing time and improve tissue recovery. [194-195]
  6. Peptides have the ability to support the structure of damaged tissues while allowing them to heal. [196]
  7. Peptides enhance tissue regeneration by promoting chondrogenesis, the process by which cartilage is developed. [197-200]
  8. By promoting cell adhesion, ipamorelin and other peptides can enhance cartilage tissue repair. [201-203]

J. Improves Sleep Quality

Ipamorelin and other growth hormone-releasing peptides play an integral role in promoting restful sleep. Studies show that by increasing GH and IGF-1 levels, as well as enhancing certain sleep processes, ipamorelin significantly improves sleep quality and quantity:

  1. In normal men, the administration of growth hormone-releasing peptide increased slow-wave sleep (SWS), which is often referred to as deep sleep. [204]
  2. In young healthy men, intravenous injections of growth hormone-releasing peptides during sleep consistently stimulated slow-wave sleep. [205]
  3. In normal young males, the administration of growth hormone releasing peptide increased stage 2 sleep. [206]
  4. By increasing GH levels, ipamorelin significantly improves the deep sleep stage. [207-212]
  5. By increasing IGF-1 levels, ipamorelin promotes deep sleep. [213-223]
  6. In rats, growth hormone releasing peptide administration activated sleep regulatory neurons in the brain. [224]

Associated Side Effects of Ipamorelin

Ipamorelin side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on ipamorelin. However, these side effects werenā€™t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of ipamorelin. Despite this, it was listed as a side effect associated with ipamorelin even though these associated side effects are very uncommon.

Side effects associated with ipamorelin may include the following:

  • Changes in taste
  • Chest tightness
  • Difficulty swallowing
  • Drowsiness
  • Dry mouth
  • Flushing of the skin
  • Headache
  • Hives
  • Hyperactivity
  • Increased hunger
  • Nausea
  • Vomiting

Ipamorelin Dosage

Ipamorelin, a growth hormone secretagogue, is widely used for its ability to stimulate the release of growth hormone (GH) without significantly affecting other hormones such as cortisol or prolactin. The typical dosage of Ipamorelin can vary based on the individual’s goals, health status, and specific medical advice. For general anti-aging purposes and overall health improvement, a common dosage range is between 200-300 micrograms (mcg) per day, administered via subcutaneous injection. For those seeking more pronounced muscle growth, fat loss, or athletic performance enhancement, the dosage may be increased to 300-600 mcg per day, divided into multiple doses to optimize GH pulses throughout the day.

The administration of Ipamorelin is usually done through subcutaneous injections, which can be self-administered with proper training. Timing of the dosage plays a crucial role in maximizing its benefits. For anti-aging and general health purposes, it is often recommended to take the injection once daily, preferably before bedtime. This aligns with the bodyā€™s natural GH secretion pattern, which peaks during sleep. For athletes and bodybuilders aiming for muscle growth and recovery, dividing the total daily dosage into two or three smaller injections throughout the day can enhance the GH response. Common times for these injections include pre-workout, post-workout, and before bedtime, ensuring a steady stimulation of GH release.

While Ipamorelin is generally considered safe and well-tolerated, it is essential to monitor its usage closely, especially when adjusting dosages. Overuse or incorrect administration can lead to potential side effects such as headaches, dizziness, and injection site reactions. It is crucial to start with the lower end of the dosage range, especially for new users, and gradually adjust based on individual responses and goals. Regular consultations with a healthcare provider are recommended to monitor progress, assess any side effects, and make necessary dosage adjustments. Blood tests to check GH levels and overall endocrine function can also help ensure that the therapy is both safe and effective. By adhering to these guidelines, users can maximize the benefits of Ipamorelin while minimizing risks.

Ipamorelin VS Sermorelin

Mechanism of Action: Ipamorelin vs. Sermorelin

Ipamorelin and Sermorelin are both peptides designed to stimulate the release of growth hormone, but they operate through different mechanisms. Ipamorelin is a growth hormone secretagogue and a ghrelin receptor agonist, which means it mimics the action of ghrelin, the “hunger hormone.” By binding to ghrelin receptors, Ipamorelin directly stimulates the pituitary gland to secrete growth hormone without significantly affecting levels of other hormones like cortisol or prolactin. In contrast, Sermorelin is an analog of growth hormone-releasing hormone (GHRH). It mimics the natural GHRH produced by the hypothalamus, thereby stimulating the pituitary gland to release growth hormone. Sermorelinā€™s action is more holistic as it relies on the body’s existing endocrine pathways.

Benefits and Applications

Both Ipamorelin and Sermorelin are used for their anabolic and rejuvenative properties, but their applications may differ slightly due to their mechanisms. Ipamorelin is often favored in the bodybuilding and athletic communities for its potent effects on muscle growth, fat reduction, and recovery without the unwanted increase in other hormones. This makes it a safer option for prolonged use, reducing the risk of side effects. Sermorelin, on the other hand, is commonly used in anti-aging treatments due to its ability to enhance the bodyā€™s natural growth hormone production. It is known to improve sleep quality, increase energy levels, promote weight loss, and enhance overall vitality, making it suitable for those looking to mitigate the effects of aging.

Safety and Side Effects

The safety profiles of Ipamorelin and Sermorelin are generally favorable, but there are important differences to note. Ipamorelin’s targeted mechanism minimizes the risk of side effects related to hormone imbalances, such as elevated cortisol or prolactin, making it a safer option for many users. Common side effects may include mild injection site reactions and headaches. Sermorelin, while also well-tolerated, can cause broader endocrine effects due to its upstream stimulation of the growth hormone-releasing pathway. This can occasionally result in side effects like nausea, dizziness, or flushing, although these are typically mild and short-lived. Both peptides should be administered under medical supervision, especially for individuals with preexisting health conditions or those on other medications, to ensure safe and effective therapy tailored to individual needs.

Ipamorelin Buy

Factors to Consider When Buying Ipamorelin

When considering purchasing Ipamorelin, it’s essential to prioritize safety, quality, and legality. Ipamorelin is a synthetic peptide that requires precise manufacturing standards to ensure its efficacy and safety. Buyers should seek reputable sources, preferably those with good reviews and certifications indicating adherence to Good Manufacturing Practices (GMP). These certifications ensure that the product has been manufactured in a controlled environment, minimizing the risk of contamination or incorrect dosing. Additionally, consulting with a healthcare professional before making a purchase is crucial to confirm the appropriateness of Ipamorelin for your health needs and to understand the correct usage and potential risks.

Sources and Purchasing Options

There are various avenues through which one can purchase Ipamorelin, including online vendors, specialty pharmacies, and research supply companies. Online vendors are a popular choice due to convenience, but it’s crucial to thoroughly vet these sources. Look for vendors that provide detailed product information, batch testing results, and have positive customer reviews. Specialty pharmacies may offer Ipamorelin with a prescription, providing a higher assurance of quality and authenticity. Research supply companies typically sell Ipamorelin for laboratory use and might not guarantee the same quality standards for human use. Regardless of the source, ensuring that the product is stored and handled correctly during shipping is vital to maintain its integrity and effectiveness.

Tesamorelin vs Ipamorelin

Mechanism of Action: Tesamorelin vs. Ipamorelin

Tesamorelin and Ipamorelin are both synthetic peptides used to stimulate the production of growth hormone (GH), but they do so via different mechanisms. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It acts by stimulating the pituitary gland to release GH, which in turn promotes lipolysis, particularly beneficial for reducing visceral fat in patients with HIV-associated lipodystrophy. Ipamorelin, on the other hand, is a growth hormone secretagogue and ghrelin receptor agonist. It mimics the action of ghrelin, the “hunger hormone,” thereby stimulating the release of GH without significantly affecting levels of other hormones like cortisol or prolactin. This targeted approach makes Ipamorelin a popular choice for those looking to enhance muscle growth and recovery with minimal side effects.

Clinical Applications and Benefits

Tesamorelin is primarily approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Its efficacy in this specific application has been well-documented, showing significant reductions in visceral adipose tissue and improvements in body composition. Tesamorelin’s benefits extend beyond fat reduction; it has been observed to improve cognitive function and cardiovascular health markers in certain populations. Ipamorelin, while not as specifically targeted as Tesamorelin, is widely used in the bodybuilding and fitness community for its anabolic effects. It promotes muscle growth, enhances recovery, and improves overall physical performance. Unlike some other growth hormone secretagogues, Ipamorelin is known for its minimal side effects, particularly the lack of impact on hunger and blood sugar levels, making it a versatile option for various therapeutic and enhancement purposes.

Side Effects and Safety Profile

Both Tesamorelin and Ipamorelin have relatively favorable safety profiles, but they come with distinct side effects and considerations. Tesamorelin’s most common side effects include injection site reactions, joint pain, and potential increases in blood glucose levels, which necessitates caution in diabetic patients. There are also concerns about its long-term impact on glucose metabolism and potential cardiovascular risks, although these are generally outweighed by its benefits in treating HIV-associated lipodystrophy. Ipamorelin, praised for its clen side effect profile, may still cause mild reactions such as headaches, dizziness, or injection site discomfort. However, it does not significantly alter cortisol or prolactin levels, making it a safer option for long-term use compared to other GH secretagogues. Both peptides require medical supervision to ensure safe and effective use, tailored to individual health conditions and goals.

Ipamorelin Dosage and Timing

Understanding Ipamorelin Dosage

Ipamorelin, a popular growth hormone secretagogue, is typically administered via subcutaneous injection. The optimal dosage can vary based on individual goals and needs, but standard dosing ranges from 200 to 300 micrograms per injection. For those seeking general anti-aging benefits or recovery enhancement, a lower dose around 200 micrograms may be sufficient. In contrast, individuals aiming for significant muscle growth and performance improvements might opt for higher doses up to 300 micrograms. Itā€™s important to note that dosing should always be personalized and ideally overseen by a healthcare professional to ensure safety and effectiveness.

Timing for Maximum Efficacy

The timing of Ipamorelin administration plays a crucial role in maximizing its efficacy. Ipamorelin is often injected two to three times daily, with one of the injections ideally taken before bedtime. This timing takes advantage of the body’s natural growth hormone release cycle, which peaks during deep sleep. An additional injection can be administered in the morning to boost GH levels throughout the day, particularly beneficial for those involved in intense physical training or seeking enhanced recovery. Spacing the injections throughout the day helps maintain elevated GH levels, providing sustained anabolic and metabolic benefits.

Combining Ipamorelin with Other Peptides

For enhanced results, Ipamorelin is frequently used in combination with other peptides like CJC-1295, which is a growth hormone-releasing hormone (GHRH) analog. This combination can amplify the release of growth hormone, as CJC-1295 and Ipamorelin work synergistically. The typical regimen involves injecting Ipamorelin alongside CJC-1295, either in the same syringe or separately, depending on the protocol prescribed. This combined approach can further optimize GH pulsatility and prolong the overall duration of growth hormone activity in the body. As with any peptide regimen, combining peptides should be done under medical supervision to monitor for potential side effects and to adjust dosages for individual response and goals.

Ipamorelin vs MK 677

Mechanism of Action: Ipamorelin vs MK-677

Ipamorelin and MK-677 are both popular growth hormone secretagogues, but they differ significantly in their mechanisms of action. Ipamorelin is a synthetic peptide that mimics ghrelin, the natural hormone that stimulates the release of growth hormone (GH) from the pituitary gland. It is administered via subcutaneous injection, and it specifically targets GH release without significantly affecting other hormones like cortisol or prolactin. MK-677, also known as Ibutamoren, is an orally active non-peptide that also mimics ghrelin and stimulates GH release. However, MK-677 has a broader systemic effect and is known to increase the levels of IGF-1 (insulin-like growth factor-1), which contributes to its anabolic properties. The key difference lies in their administration methods and the specificity of their action on GH release.

Efficacy and Usage

Both Ipamorelin and MK-677 are used for their growth hormone-boosting effects, but they cater to slightly different user needs and preferences. Ipamorelin is favored by those who prefer a more targeted and controlled GH release with fewer off-target effects. It is often used in anti-aging treatments, for muscle growth, and to enhance recovery from injuries. The injectable nature of Ipamorelin allows for precise dosing and timing, making it ideal for users who are comfortable with injections and seeking a controlled regimen. On the other hand, MK-677’s oral administration makes it convenient and appealing to users who prefer not to deal with injections. Its broad systemic effects, including a significant increase in IGF-1 levels, make it a popular choice for those looking to enhance overall body composition, improve sleep quality, and increase appetite.

Side Effects and Considerations

When comparing Ipamorelin and MK-677, it’s important to consider their side effect profiles. Ipamorelin is generally well-tolerated, with minimal side effects due to its selective action on GH release. Some users may experience mild injection site reactions, but it does not significantly impact cortisol or prolactin levels, reducing the risk of unwanted hormonal imbalances. MK-677, while convenient, can have a broader range of side effects due to its systemic action. Users may experience increased appetite, water retention, and transient increases in blood sugar and insulin resistance. Additionally, MK-677’s impact on the entire endocrine system necessitates careful monitoring, particularly for individuals with underlying health conditions. Ultimately, the choice between Ipamorelin and MK-677 depends on the user’s goals, preferences for administration, and their tolerance for potential side effects.

Ipamorelin Cost

Sure, discussing the cost of Ipamorelin typically involves considering several factors. Ipamorelin is a synthetic peptide used to stimulate the production of growth hormone in the body, often used in anti-aging and bodybuilding circles. The cost of Ipamorelin can vary significantly based on factors such as the supplier, dosage strength, and the frequency of administration. Generally, Ipamorelin is sold in vials containing a specific amount of the peptide, and prices can range from approximately $20 to $40 per vial, depending on the supplier and the quantity purchased.

The total cost of Ipamorelin also includes considerations for how often it needs to be administered. Some users take Ipamorelin daily, while others may use it a few times a week. This frequency can impact the overall monthly cost, with daily users typically spending more compared to those who use it less frequently. Additionally, the method of administration, whether subcutaneous injection or oral ingestion (if available), can also affect pricing due to differences in bioavailability and manufacturing costs associated with each method.

When considering the cost of Ipamorelin, it’s essential to factor in potential additional expenses such as syringes for injections, alcohol swabs, and shipping fees if purchasing online. Moreover, the source of Ipamorelin, such as a reputable supplier or pharmacy, can influence pricing and reliability. It’s crucial for individuals interested in Ipamorelin therapy to research suppliers thoroughly, ensuring they are obtaining a high-quality product at a reasonable cost to maximize the potential benefits and minimize risks. Additionally, ongoing costs for Ipamorelin therapy, including regular consultations with healthcare providers and potential adjustments in dosage, should be considered to achieve optimal results. Understanding these factors helps in planning and budgeting effectively for a successful Ipamorelin therapy experience.

Ipamorelin Stack

Ipamorelin is often stacked with other peptides or compounds to enhance its effects, particularly in the realm of fitness and anti-aging. One common stack involves combining Ipamorelin with other growth hormone-releasing peptides (GHRPs) like GHRP-2 or GHRP-6. These peptides work synergistically to stimulate the release of growth hormone from the pituitary gland, leading to increased levels of insulin-like growth factor 1 (IGF-1) and promoting muscle growth and recovery. The combination is believed to amplify the overall growth hormone pulse, potentially yielding greater benefits in terms of muscle gain, fat loss, and overall body composition improvements.

Another popular stack for Ipamorelin involves combining it with CJC-1295, a growth hormone-releasing hormone (GHRH) analog. This combination is designed to maximize the stimulation of growth hormone release. CJC-1295 extends the half-life of Ipamorelin by inhibiting its degradation and prolonging its effects, leading to sustained elevation of growth hormone levels throughout the day. This stack is favored by athletes and bodybuilders looking to optimize their training results, as it supports lean muscle mass development, fat metabolism, and recovery.

Additionally, Ipamorelin can be stacked with other supplements or medications depending on individual health goals and needs. Some users combine it with testosterone boosters, such as DHEA or tribulus terrestris, to enhance overall hormone balance and further augment muscle growth and energy levels. However, when stacking Ipamorelin or any peptide, it’s essential to consult with a healthcare provider or a knowledgeable professional to ensure safety, efficacy, and compatibility with individual health conditions and goals. Proper dosing and timing are crucial to maximize the benefits while minimizing potential side effects or interactions.

What is Ipamorelin Used For?

Ipamorelin is primarily used for its growth hormone-releasing properties, making it popular in the fields of fitness, bodybuilding, and anti-aging. As a synthetic peptide, it stimulates the pituitary gland to increase the production of growth hormone, which in turn elevates levels of insulin-like growth factor 1 (IGF-1). This hormonal boost can help in building lean muscle mass, reducing body fat, and enhancing overall body composition. Athletes and bodybuilders often use Ipamorelin to improve muscle recovery, increase strength, and support more efficient fat loss, allowing them to achieve their training and physique goals more effectively.

Beyond its applications in fitness and bodybuilding, Ipamorelin is also valued for its potential anti-aging benefits. Growth hormone levels naturally decline with age, leading to symptoms such as decreased muscle mass, increased body fat, reduced energy levels, and diminished skin elasticity. By stimulating the release of growth hormone, Ipamorelin can help counteract these age-related changes. Users often report improvements in skin texture, increased energy, better sleep quality, and overall enhanced vitality. Its ability to promote cellular regeneration and repair also makes it appealing for those looking to slow down the aging process and maintain a youthful appearance.

Additionally, Ipamorelin is being explored for its therapeutic potential in various medical conditions associated with growth hormone deficiencies. It may be beneficial for individuals with growth hormone deficiencies, metabolic disorders, and muscle-wasting diseases. By increasing growth hormone levels, Ipamorelin can aid in improving muscle mass, bone density, and overall metabolic health in these patients. Researchers are also investigating its potential in enhancing healing and recovery from injuries, as growth hormone plays a crucial role in tissue repair and regeneration. While more clinical studies are needed to fully understand and validate these therapeutic uses, the preliminary results are promising, indicating a wide range of applications for Ipamorelin beyond just fitness and anti-aging.

Share This Page

FAQ

What does Ipamorelin do to the body?

Ipamorelin stimulates the release of more growth hormone, promoting muscle growth, fat loss, and tissue repair in the body. By triggering the pituitary gland to secrete more growth hormone, Ipamorelin enhances the body’s natural growth processes, leading to improved muscle mass and strength. Additionally, the increased production of more growth hormone helps in the efficient breakdown of fat and accelerates the repair and regeneration of tissues, contributing to overall better physical performance and recovery.

What is the downside of Ipamorelin?Ā Ā Ā Ā 

The downside of Ipamorelin includes potential side effects such as water retention, joint pain, and an increased risk of insulin resistance. Despite these concerns, ipamorelin peptide therapy has been widely used for its significant benefits in promoting muscle growth and fat loss. Additionally, ipamorelin peptide therapy can aid in tissu e repair and enhance overall physical performance, making it a popular choice among athletes and individuals seeking improved body composition. However, it is important to monitor these potential side effects closely to ensure the therapy’s safety and effectiveness.

Does Ipamorelin increase testosterone?Ā Ā Ā Ā Ā Ā 

No, Ipamorelin does not directly increase testosterone; it primarily stimulates the release of growth hormone. This stimulation leads to several benefits, including increased bone density, which can be particularly beneficial for individuals at risk of osteoporosis. By enhancing growth hormone levels, Ipamorelin contributes to improved muscle growth, fat loss, and tissue repair. Additionally, the increase in growth hormone can indirectly support increased bone density, promoting stronger bones and reducing the likelihood of fractures. While Ipamorelin is not a direct testosterone booster, its effects on growth hormone can provide comprehensive health benefits, including enhanced bone strength and overall physical performance.

What does Ipamorelin do for bodybuilding?Ā 

Ipamorelin promotes muscle growth and fat loss in bodybuilding by stimulating the release of growth hormone, which enhances protein synthesis and recovery. As part of the growth factor family, this peptide works by mimicking the body’s natural growth hormone-releasing mechanisms, providing a more targeted approach to muscle development and fat reduction. The growth factor family, to which Ipamorelin belongs, plays a crucial role in various physiological processes, including cellular growth, proliferation, and differentiation. By leveraging these mechanisms, Ipamorelin helps athletes and bodybuilders achieve their fitness goals more effectively and efficiently.

What does the Ipamorelin peptide do?

The Ipamorelin peptide stimulates the release of growth hormone, promoting muscle growth, fat loss, and overall improved body composition. By enhancing the body’s natural functions, Ipamorelin helps optimize protein synthesis and recovery, making it a valuable tool for athletes and bodybuilders. Additionally, Ipamorelin aligns with the body’s natural functions by mimicking the endogenous growth hormone-releasing processes, ensuring a balanced and efficient approach to achieving fitness goals. This targeted stimulation supports muscle development, reduces fat, and improves overall physical performance.

Why was Ipamorelin discontinued?Ā Ā Ā Ā Ā Ā Ā 

The Ipamorelin peptide stimulates the release of growth hormone, promoting muscle growth, fat loss, and overall improved body composition. Additionally, Ipamorelin has beneficial effects on the cardiovascular system, enhancing cardiovascular health through improved metabolic function and reduced body fat. By promoting more efficient growth hormone release, Ipamorelin supports the cardiovascular system’s overall function, contributing to better heart health and circulation. These combined benefits make Ipamorelin a valuable peptide for individuals looking to enhance their body’s natural functions, including the cardiovascular system, leading to improved overall health and well-being.

When should you take Ipamorelin?Ā Ā 

When considering the cost of Ipamorelin, it’s essential to factor in potential additional expenses such as syringes for injections, alcohol swabs, and shipping fees if purchasing online. Moreover, the source of Ipamorelin, such as a reputable supplier or pharmacy, can influence pricing and reliability. It’s crucial for individuals interested in Ipamorelin therapy to research suppliers thoroughly, ensuring they are obtaining a high-quality product at a reasonable cost to maximize the potential benefits and minimize risks. Additionally, ongoing costs for Ipamorelin therapy, including regular consultations with healthcare providers and potential adjustments in dosage, should be considered to achieve optimal results. Understanding these factors helps in planning and budgeting effectively for a successful Ipamorelin therapy experience. Ipamorelin therapy is often used to treat diseases associated with growth hormone deficiencies and related conditions. Finally, Ipamorelin is typically taken before bedtime to maximize growth hormone release during sleep.

Is Ipamorelin being discontinued?

When considering the cost of Ipamorelin, it’s essential to factor in potential additional expenses such as syringes for injections, alcohol swabs, and shipping fees if purchasing online. Moreover, the source of Ipamorelin, such as a reputable supplier or pharmacy, can influence pricing and reliability. It’s crucial for individuals interested in Ipamorelin therapy to research suppliers thoroughly, ensuring they are obtaining a high-quality product at a reasonable cost to maximize the potential benefits and minimize risks. Additionally, ongoing costs for Ipamorelin therapy, including regular consultations with healthcare providers and potential adjustments in dosage, should be considered to achieve optimal results. Understanding these factors helps in planning and budgeting effectively for a successful Ipamorelin therapy experience. Ipamorelin therapy is often used to treat diseases associated with growth hormone deficiencies and related conditions. Notably, Ipamorelin does not directly affect testosterone levels, making it a suitable option for those specifically looking to increase growth hormone without impacting testosterone. Finally, Ipamorelin is typically taken before bedtime to maximize growth hormone release during sleep. As of now, there are no indications that Ipamorelin is being discontinued.

Should I take sermorelin and Ipamorelin together?Ā Ā Ā 

Consult with a healthcare professional before taking Sermorelin and Ipamorelin together to ensure it is safe and appropriate for your specific health needs. These peptides are often used for their anti-aging properties, which include improved skin elasticity, increased muscle mass, and reduced body fat. By stimulating the production of growth hormone, they can help enhance vitality and overall well-being.

What are the best peptides for muscle growth?

The best peptides for muscle growth are typically considered to be Ipamorelin, CJC-1295, and BPC-157. These peptides are typically combined in various regimens to maximize their synergistic effects on muscle development and recovery. By using these peptides together, individuals can achieve more significant improvements in muscle mass, strength, and overall physical performance.

Does Ipamorelin really work?Ā Ā Ā 

Yes, Ipamorelin is effective in stimulating the release of growth hormone, promoting muscle growth, fat loss, and improved recovery. However, it is important to consult with a healthcare professional to review your medical history before starting Ipamorelin. This ensures the peptide therapy is safe and appropriate for your specific health needs, considering any pre-existing conditions or medications you may be taking.

What are the benefits of Tesamorelin Ipamorelin?Ā Ā Ā Ā Ā Ā Ā Ā Ā 

The benefits of Tesamorelin and Ipamorelin include increased growth hormone release, enhanced muscle growth, fat reduction, and improved recovery and overall body composition. Additionally, these peptides can contribute to better mental clarity, which can enhance cognitive function and overall well-being. By stimulating growth hormone release, Tesamorelin and Ipamorelin not only support physical health but also promote mental clarity, making them valuable options for those looking to improve both body and mind.

Does Tesamorelin build muscle?Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā 

Yes, Tesamorelin can help build muscle by stimulating the release of growth hormone. However, it is important to be aware of potential side effects, which can include flu-like symptoms such as fatigue, fever, and body aches. These symptoms can vary in intensity and duration, so it is crucial to monitor your response to the treatment and consult with a healthcare professional if they persist or worsen.

What's the best peptide for weight loss?Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā 

The best peptide for weight loss is often considered to be Tesamorelin, which can reduce abdominal fat in individuals with HIV-associated lipodystrophy. Additionally, Tesamorelin helps increase muscle mass, which can lead to a higher metabolic rate, thereby burning more calories even at rest. This combination of fat reduction and muscle mass increase makes Tesamorelin a potent option for those looking to improve body composition and overall health.

Does Tesamorelin increase growth hormone?Ā Ā Ā 

Yes, Tesamorelin increases growth hormone levels by stimulating the pituitary gland. The use of these two peptides, Tesamorelin and another growth hormone-releasing peptide, can provide synergistic effects for enhanced fat loss and muscle gain. By combining the benefits of both, individuals may experience improved body composition and overall health.

What is the difference between MK-677 and CJC-1295?

MK-677 is an oral growth hormone secretagogue that mimics ghrelin, while CJC-1295 is an injectable peptide that stimulates growth hormone release by acting as a growth hormone-releasing hormone (GHRH) analog. Determining who is a good candidate for these peptides depends on individual health goals and medical history. People seeking muscle growth, fat loss, or improved recovery might benefit from these treatments, but it’s crucial to consult with a healthcare professional to ensure safety and appropriateness for their specific needs.

What is similar to MK-677?Ā Ā Ā Ā Ā Ā Ā Ā 

Ibutamoren (MK-677) is similar to GHRP-6 (Growth Hormone Releasing Peptide-6) as both are growth hormone secretagogues that stimulate the release of growth hormone.

Does MK-677 increase muscle mass?

Ā Yes, MK-677 increases muscle mass by stimulating the release of growth hormone and insulin-like growth factor 1 (IGF-1).

Does MK-677 increase growth hormone levels?

Ā Yes, MK-677 increases growth hormone levels by stimulating the release of growth hormone and insulin-like growth factor 1 (IGF-1).

Does Ipamorelin require a prescription?Ā 

Ā Yes, Ipamorelin requires a prescription.

What is the price of Ipamorelin peptide?Ā Ā Ā 

Ā The price of Ipamorelin peptide varies but typically ranges from $150 to $300 per month.

What to stack with CJC-1295 and Ipamorelin?Ā 

Ā CJC-1295 and Ipamorelin are often stacked with GHRP-6 or GHRP-2 to enhance growth hormone release and muscle growth.

What are the best peptides to get ripped?

Ā The best peptides to get ripped include CJC-1295, Ipamorelin, and GHRP-6, as they help increase muscle mass, promote fat loss, and enhance recovery.

What are the benefits of Ipamorelin?

The benefits of Ipamorelin include increased muscle growth, enhanced fat loss, improved recovery, better sleep quality, and anti-aging effects.

Reference

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.

  2. JimƩnez-reina L, CaƱete R, De la torre MJ, Bernal G. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002;17(3):707-14.

  3. Gobburu JV, AgersĆø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6.

  4. Thomas A, Delahaut P, Krug O, SchƤnzer W, Thevis M. Metabolism of growth hormone releasing peptides. Anal Chem. 2012;84(23):10252-9.

  5. Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083-92.

  6. Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal. 2015;7(10):919-25.

  7. Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal. 2015;7(10):919-25.

  8. Hansen TK, Ankersen M, Raun K, Hansen BS. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1915-8.

  9. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology. 2008;154(3):557-568. doi:10.1038/bjp.2008.153.

  10. Tavares ABW, Micmacher E, Biesek S, et al. Effects of Growth Hormone Administration on Muscle Strength in Men over 50 Years Old. International Journal of Endocrinology. 2013;2013:942030. doi:10.1155/2013/942030.

  11. Devesa J, AlmenglĆ³ C, Devesa P. Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth? Clinical Medicine Insights Endocrinology and Diabetes. 2016;9:47-71. doi:10.4137/CMED.S38201.

  12. Taaffe DR, Pruitt L, Reim J, et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab. 1994;79(5):1361-6.

  13. Weber MM. Effects of growth hormone on skeletal muscle. Horm Res. 2002;58 Suppl 3:43-8.

  14. Welle S, Thornton C, Statt M, Mchenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab. 1996;81(9):3239-43.

  15. Sotiropoulos A, Ohanna M, Kedzia C, et al. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(19):7315-7320. doi:10.1073/pnas.0510033103.

  16. Gonzalez S, Sathyapalan T, Javed Z, Atkin SL. Effects of Growth Hormone Replacement on Peripheral Muscle and Exercise Capacity in Severe Growth Hormone Deficiency. Front Endocrinol (Lausanne). 2018;9:56.

  17. Peroni CN, Hayashida CY, Nascimento N, et al. Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient Little mice. Clinics. 2012;67(3):265-272. doi:10.6061/clinics/2012(03)11.

  18. Berlanga-Acosta J, Abreu-Cruz A, Barco Herrera DG, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clinical Medicine Insights Cardiology. 2017;11:1179546817694558. doi:10.1177/1179546817694558.

  19. Lim CJ, Jeon JE, Jeong SK, et al. Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I. BMB Reports. 2015;48(9):501-506. doi:10.5483/BMBRep.2015.48.9.258.

  20. Haruta I, Fuku Y, Kinoshita K, et al. One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. Journal of Cachexia, Sarcopenia and Muscle. 2015;6(3):237-241. doi:10.1002/jcsm.12028.

  21. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci. 2001;2:551ā€“560.

  22. Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev. 2009;61:430ā€“481.

  23. LaferrĆØre B, Abraham C, Russell CD, Bowers CY. Growth Hormone Releasing Peptide -2 (GHRP-2), like ghrelin, increases food intake in healthy men. The Journal of clinical endocrinology and metabolism. 2005;90(2):611-614. doi:10.1210/jc.2004-1719.

  24. Zhou S, Salisbury J, Preedy VR, Emery PW. Increased collagen synthesis rate during wound healing in muscle. PLoS One. (2013);8:e58324. doi: 10.1371/journal.pone.0058324.

  25. Bonaldo P, Braghetta P, Zanetti M, Piccolo S, Volpin D, Bressan GM. Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum Mol Genet. (1998);7:2135ā€“2140. doi: 10.1093/hmg/7.13.2135.

  26. Takano H, Komuro I, Oka T, et al. The Rho family G proteins play a critical role in muscle differentiation. Mol Cell Biol. (1998);18:1580ā€“1589. doi: 10.1128/MCB.18.3.1580.

  27. Schwander M, Leu M, Stumm M, et al. Beta1 integrins regulate myoblast fusion and sarcomere assembly. Dev Cell. (2003);4:673ā€“685. doi: 10.1016/S1534-5807(03)00118-7.

  28. Andersen NB, Malmlƶf K, Johansen PB, Andreassen TT, Ƙrtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-72.

  29. Mericq V, Cassorla F, Salazar T, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998;83(7):2355-60.

  30. Bellone J, Ghizzoni L, Aimaretti G, et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. 1995;133(4):425-9.

  31. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-60.

  32. Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam GR. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab. 2003;16:981ā€“985.

  33. Pihoker C, Kearns GL, French D, Bowers CY. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. J Clin Endocrinol Metab. 1998;83(4):1168ā€“1172.

  34. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13.

  35. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-77.

  36. Svensson, J., Lall, S., Dickson, S. L., Bengtsson, B. A., RĆømer, J., Ahnfelt-RĆønne, I., Ohlsson, C., & Jansson, J. O. (2001). Effects of growth hormone and its secretagogues on bone. Endocrine, 14(1), 63ā€“66. https://doi.org/10.1385/ENDO:14:1:063.

  37. Guo S, Gao Q, Jiao Q, Hao W, Gao X, Cao JM. Gastric mucosal damage in water immersion stress: mechanism and prevention with GHRP-6. World J Gastroenterol. 2012;18(24):3145ā€“3155.

  38. Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut. 2006;55(3):327-33.

  39. Haruta I, Fuku Y, Kinoshita K, et al. One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. Journal of Cachexia, Sarcopenia and Muscle. 2015;6(3):237-241. doi:10.1002/jcsm.12028.

  40. Beck DE, Sweeney WB, Mccarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34.

  41. Depoortere I, De Winter B, Thijs T, De Man J, Pelckmans P, Peeters T. Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro. Eur J Pharmacol. 2005;515(1ā€“3):160ā€“168.

  42. Kitazawa T, De Smet B, Verbeke K, Depoortere I, Peeters TL. Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro. Gut. 2005;54(8):1078ā€“1084.

  43. Xu L, Depoortere I, Tomasetto C, et al. Evidence for the presence of motilin, ghrelin, and the motilin and ghrelin receptor in neurons of the myenteric plexus. Regul Pept. 2005;124(1ā€“3):119ā€“125.

  44. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology. 2012;4:149-155. doi:10.2147/JEP.S35396.

  45. Qiu WC, Wang ZG, Wang WG, Yan J, Zheng Q. Gastric motor effects of ghrelin and growth hormone releasing peptide 6 in diabetic mice with gastroparesis. World J Gastroenterol. 2008;14(9):1419-24.

  46. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110ā€“1116.

  47. Fazio S. Sabatini D. Capaldo B. et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy N. Engl. J. Med.Ā  1996 334 809 814.

  48. Broglio F. Guarracino F. Benso A. et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery Eur. J. Pharmacol.Ā  2002 448 193 200.

  49. Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G, Arvat E, Boghen MF, Deghengi R, Muccioli G, Ong H, Ghigo E 1999 Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 22:266ā€“272.

  50. Bisi G, Podio V, Valetto MR, et al. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GHā€“releasing peptide, in humans. J Endocrinol Invest 1999 ; 224 : 266-72.

  51. Valetto MR, Podio V, Broglio F et al. The acute administration of Hexarelin, a peptidyl GH secretagogues, has GH-independent, positive inotropic effect in humans. In : Hormones and the Heart, Naples, Italy 1998 ; abs. p. 54.

  52. Ghigo E, Arvat E, Gianotti L et al. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab 1994 ; 78 : 693-8.

  53. Rahim A, Oā€™Neill PA, Shalet SM. Growth hormone status -during long-term hexarelin therapy. J Clin Endocrinol Metab 1998 ; 83 : 1644-9.

  54. Vasan RS, Sullivan LM, Dā€™agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2003;139(8):642-8.

  55. Locatelli V. Rossoni G. Schweiger F. et al. Growth hormone independent cardioprotective effects of hexarelin in the rat EndocrinologyĀ  1999 140 4024 4031.

  56. Tivesten A. Bollano E. Caidahl K. et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction EndocrinologyĀ  2000 141 60 66.

  57. Xu X.B. Cao J.M. Pang J.J. et al. The positive inotropic and calcium-mobilizing effects of growth hormone-releasing peptides on rat heart EndocrinologyĀ  2003 144 5050 5057.

  58. Titterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth Hormone-Releasing Peptide-2 Suppresses Vascular Oxidative Stress in ApoEāˆ’/āˆ’ Mice But Does Not Reduce Atherosclerosis. Endocrinology. 2009;150(12):5478-5487. doi:10.1210/en.2009-0283.

  59. Iwase M. Kanazawa H. Kato Y. et al. Growth-hormone releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters Cardiovasc. Res.Ā  2004 61 30 38.

  60. Shen Y.T. Lynch J.J. Hargreaves R.J. Gould R.J. A growth hormone secretagogue prevents ischemic-induced mortality independently of the growth hormone pathway in dogs with chronic dilated cardiomyopathy J. Pharmacol. Exp. Ther. 2003 306 815 820.

  61. Berlanga J, Cibrian D, Guevara L, et al. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci. 2007;112(4):241-50.

  62. Catalina PF, Mallo F, Andrade MA, Garcƭa-mayor RV, DiƩguez C. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. J Clin Endocrinol Metab. 1998;83(10):3663-7.

  63. Villares R, Kakabadse D, Juarranz Y, Gomariz RP, MartĆ­nez-a C, Mellado M. Growth hormone prevents the development of autoimmune diabetes. Proc Natl Acad Sci USA. 2013;110(48):E4619-27.

  64. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004;25(6):403-6.

  65. Granado M, Garcƭa-cƔceres C, Tuda M, Frago LM, Chowen JA, Argente J. Insulin and growth hormone-releasing peptide-6 (GHRP-6) have differential beneficial effects on cell turnover in the pituitary, hypothalamus and cerebellum of streptozotocin (STZ)-induced diabetic rats. Mol Cell Endocrinol. 2011;337(1-2):101-13.

  66. Johansen PB, Segev Y, Landau D, Phillip M, Flyvbjerg A. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Exp Diabesity Res. 2003;4(2):73-81.

  67. Bailey CJ, Wilkes LC, Flatt PR, Conlon JM, Buchanan KD. Effects of growth hormone-releasing hormone on the secretion of islet hormones and on glucose homeostasis in lean and genetically obese-diabetic (ob/ob) mice and normal rats. J Endocrinol (1989) 123(1):19ā€“24.10.1677/joe.0.1230019.

  68. Ludwig B, Ziegler CG, Schally AV, Richter C, Steffen A, Jabs N, et al. Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc Natl Acad Sci U S A (2010) 107(28):12623ā€“8.10.1073/pnas.1005098107.

  69. Ludwig B, Rotem A, Schmid J, Weir GC, Colton CK, Brendel MD, et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A (2012) 109(13):5022ā€“7.10.1073/pnas.1201868109.

  70. Zhang X, Cui T, He J, Wang H, Cai R, Popovics P, et al. Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice. Proc Natl Acad Sci U S A (2015) 112(44):13651ā€“6.10.1073/pnas.1518540112.

  71. Schubert U, Schmid J, Lehmann S, Zhang XY, Morawietz H, Block NL, et al. Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone. Proc Natl Acad Sci U S A (2013) 110(6):2288ā€“93.10.1073/pnas.1221505110.

  72. Schmid J, Ludwig B, Schally AV, Steffen A, Ziegler CG, Block NL, et al. Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11beta-hydroxysteroid dehydrogenase. Proc Natl Acad Sci U S A (2011) 108(33):13722ā€“7.10.1073/pnas.1110965108.

  73. Perboni S, Bowers C, Kojima S, Asakawa A, Inui A. Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice. World J Gastroenterol. 2008;14(41):6303ā€“6305.

  74. Abbassi V, BellantiĀ  Ā  Humoral a cell-mediated Ā  immunity in growth hormone-deficientĀ  children: effect of therapy with human growth hormone. Pediat Res 1985; 19: 299-301.

  75. Rapaport R, Oleske J, Aldich H, Salomon S, Delfaus C, Denny T. Suppression of immune function in Ā  growth Ā  hormone-deficient Ā  children Ā  during Ā  treatment Ā  with Ā  human Ā  growth hormone. J Pediatr 1986; 109; 434-439.

  76. Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288(3):E486-E492.

  77. Cao Y, Tang J, Yang T, et al. Cardioprotective effect of ghrelin in cardiopulmonary bypass involves a reduction in inflammatory response. PLoS One. 2013;8(1):e55021.

  78. GarcĆ­a Del Barco D, Montero E, Coro-Antich RM, et al. Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis. Restor Neurol Neurosci. 2011;29(4):243ā€“252.

  79. GarcĆ­a Del Barco D, Perez-Saad H, Rodriguez V, et al. Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model. Neurotox Res. 2011;19(1):195ā€“209.

  80. Garcia Del Barco-Herrera D, Martinez NS, Coro-Antich RM, et al. Epidermal growth factor and growth hormone-releasing peptide-6: combined therapeutic approach in experimental stroke. Restor Neurol Neurosci. 2013;31(2):213ā€“223.

  81. Subiros N, Perez-Saad HM, Berlanga JA, et al. Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurol Res. 2015;38(3):187ā€“195.

  82. Martƭnez R, HernƔndez L, Gil L, et al. Growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus). Vaccine. 2017;35(42):5722-5728.

  83. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocrin Rev. 1993;14:20ā€“39.

  84. Sonntag WE, Meites J. Decline in GH secretion in aging animals and man. In: Everett AV, Walton JR, editors. Regulation of neuroendocrine aging. Karger; Basel: 1988. pp. 111ā€“124.

  85. Uberti ECD, Ambrosio MR, Cella SG, Margutti AR, Trasforini G, Rigamonti AE, Petrone E, Muller EE. Defective hypothalamic growth hormone (GH)-releasing hormone activity may contribute to declining GH secretion with age in man. J Clin Endocinol Metab. 1997;82:2885ā€“2888.

  86. Russell-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL. In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: Evidence for relative GHRH deficiency in aging. J Clin Endocinol Metab. 1999;84:3490ā€“3497.

  87. Gala RR. Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med. 1991;198(1):513-27.

  88. Gelato MC. Growth hormone-insulinlike growth factor I and immune function. Trends Endocrinol Metab. 1993;4(3):106-10.

  89. Available at https://clinicaltrials.gov/ct2/show/NCT00663611.

  90. Takagi K, Suzuki F, Barrow RE, Wolf SE, Kobayashi M, Herndon DN. Growth hormone improves immune function and survival in burned mice infected with herpes simplex virus type 1. J Surg Res. 1997;69(1):166-70.

  91. Gelato MC. Aging and immune function: a possible role for growth hormone. Horm Res. 1996;45(1-2):46-9.

  92. Rapaport R, Oleske J, Ahdieh H, Solomon S, Delfaus C, Denny T. Suppression of immune function in growth hormone-deficient children during treatment with human growth hormone. J Pediatr. 1986;109(3):434-9.

  93. Meazza C, Pagani S, Travaglino P, Bozzola M. Effect of growth hormone (GH) on the immune system. Pediatr Endocrinol Rev. 2004;1 Suppl 3:490-5.

  94. Manfredi R, Tumietto F, Azzaroli L, Zucchini A, Chiodo F, Manfredi G. Growth hormone (GH) and the immune system: impaired phagocytic function in children with idiopathic GH deficiency is corrected by treatment with biosynthetic GH. J Pediatr Endocrinol. 1994;7(3):245-51.

  95. Tesselaar K, Miedema F. Growth hormone resurrects adult human thymus during HIV-1 infection. J Clin Invest. 2008;118(3):844-7.

  96. Meazza C, Pagani S, Travaglino P, Bozzola M. Effect of growth hormone (GH) on the immune system. Pediatr Endocrinol Rev. 2004;1 Suppl 3:490-5

  97. Meazza C, Pagani S, Travaglino P, Bozzola M. Effect of growth hormone (GH) on the immune system. Pediatr Endocrinol Rev. 2004;1 Suppl 3:490-5.

  98. Saxena GB, Saxena RK, Adler WH. Regulation of natural killer activity in vivo. III. Effect of Ā  hypophysectomy Ā  and Ā  growth Ā  hormoneĀ  treatmentĀ  on Ā  the Ā  natural Ā  killer Ā  activity Ā  of Ā  the mouse spleen cell population. Int Arch Allergy Appl Immunol 1982; 67: 169-174.

  99. Kiess W, Malozowski S, Gelato M, Ā  ButenandtĀ  O, Doerr H, Crisp B, Eisl Ā  E, Ā  Maluish Ā  A, BelohradskyĀ  Ā  Ā  Lymphocyte Ā  subset Ā  distribution Ā  andĀ  natural Ā  killer Ā  activityĀ  in Ā  growth hormone deficiency before and during short-term treatment with growth hormone releasing hormone. Clin Immunol Immunopathol 1988; 48: 85-94.

  100. Bozzola M, Ā  De Ā  Amici Ā  M, Ā  Zecca Ā  M, Ā  Schimpff Ā  Ā  Rapaport Ā  M. Ā  Modulating Ā  effect Ā  of growth hormone on tumor necrosis factor-Ī± and interleukin-1Ī². Eur J Endocrinol 1998; 139: 640-643.

  101. Bozzola M, De Benedetti F, De Amici M, Jouret B,Ā  Travaglino Ā  P, Ā  PaganiĀ  S, Conte F & TauberĀ  Ā  Stimulating Ā  effectĀ  ofĀ  growth Ā  hormone on Ā  cytokineĀ  release in Ā  children.Ā  EurĀ  J Endocrinol 2003; 149: 1-5.

  102. Serri O, St-Jacques P, Sartippour M, Renier G. Alterations of monocyte function in patients with growth hormone deficiency: effect of substitutive GH therapy. J Clin Endocrinol Metab 1999; 84: 58-63.

  103. Kelley, K. W.. 1991. Growth hormone in immunobiology. R. Ader, and D. L. Felton, and N. Cohen, eds. Psychoneuroimmunology 2nd Ed.377 Academic Press, New York.

  104. Murphy, W. J., R. Hallgeir, D. L. Longo. 1995. Effects of growth hormone and prolactin in immune development and function. Life Sci. 57: 1.

  105. Clark, R.. 1997. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr. Rev. 18: 157.

  106. Smith, P. E.. 1930. Effect of hypophysectomy upon the involution of the thymus in the rat. Anat. Rec. 47: 119.

  107. Duquesnoy, R. J., G. M. Pederson. 1981. Immunology and hematologic deficiencies of the hipopituitary dwarf mouse. M. E. Gershwin, and B. Merchant, eds. In Immunology Defects in Laboratory Animals Vol. 1: 309 Plenum, New York.

  108. Gala, R. R., E. M. Shevach. 1993. Influence of prolactin and growth hormone on the activation of dwarf mouse lymphocytes in vivo. Proc. Soc. Exp. Biol. Med. 204: 224.

  109. Murphy, W. J., S. K. Durum, D. L Longo. 1992. Human growth hormone promotes engraftment of murine or human T cells in severe combined immunodeficient mice. Proc. Natl. Acad. Sci. USA 89: 4481.

  110. Taub, D. D., G. Tsarfaty, A. R. Lloyd, S. K. Durum, D. L. Longo, W. J. Murphy. 1994. Growth hormone promotes human T cells adhesion and migration to both human and murine matrix proteins in vitro and directly promotes xenogeneic engraftment. J. Clin. Inv. 94: 293.

  111. Koo GC, Huang C, Camacho R, et al. Immune enhancing effect of a growth hormone secretagogue. J Immunol. 2001;166(6):4195-201.

  112. Hersch EC, Merriam GR. Growth hormone (GH)ā€“releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus? Clinical Interventions in Aging. 2008;3(1):121-129.

  113. Aleman A, Verhaar HJ, De haan EH, et al. Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab. 1999;84(2):471-5.

  114. Vitiello MV, Schwartz RS, Buchner KE, et al. Treating age-related changes in somatotrophic hormones, sleep, and cognition. Dialogs in Clinical Neuroscience. 2001;3:229ā€“36.

  115. Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27(2):318-23.

  116. Friedman SD, Baker LD, Borson S, et al. Growth hormone-releasing hormone effects on brain Ī³-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883-90.

  117. Kim SW, Her SJ, Park SJ, et al. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone. 2005;37(3):359-69.

  118. Kim YS, Choi DH, Block ML, et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J. 2007;21(1):179-87.

  119. Banks WA, Tschƶp M, Robinson SM, Heiman ML. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther. 2002;302(2):822-7.

  120. Chung H, Seo S, Moon M, Park S. Phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3 beta and ERK1/2 pathways mediate protective effects of acylated and unacylated ghrelin against oxygen-glucose deprivation-induced apoptosis in primary rat cortical neuronal cells. J Endocrinol. 2008;198(3):511-21.

  121. Garcƭa-cƔceres C, Lechuga-sancho A, Argente J, Frago LM, Chowen JA. Death of hypothalamic astrocytes in poorly controlled diabetic rats is associated with nuclear translocation of apoptosis inducing factor. J Neuroendocrinol. 2008;20(12):1348-60.

  122. Frago LM, PaƱeda C, Dickson SL, Hewson AK, Argente J, Chowen JA. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology. 2002;143(10):4113-22.

  123. Zhang Y, Bhavnani BR. Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. BMC Neurosci. 2006;7:49.

  124. Halem HA, Taylor JE, Dong JZ, et al. A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology. 2005;81(5):339-49.

  125. Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest. 2005;115(12):3564-72.

  126. Arnoult D, Karbowski M, Youle RJ. Caspase inhibition prevents the mitochondrial release of apoptosis-inducing factor. Cell Death Differ. 2003;10(7):845-9.

  127. Rungger-brƤndle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;41(7):1971-80.

  128. Arnoult D, Karbowski M, Youle RJ. Caspase inhibition prevents the mitochondrial release of apoptosis-inducing factor. Cell Death Differ. 2003;10(7):845-9.

  129. Jiang Z, Zhang Y, Chen X, et al. Activation of Erk1/2 and Akt in astrocytes under ischemia. Biochem Biophys Res Commun. 2002;294(3):726-33.

  130. Jiang H, Betancourt L, Smith RG. Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol Endocrinol. 2006;20(8):1772-85.

  131. Frago LM, PaƱeda C, Dickson SL, Hewson AK, Argente J, Chowen JA. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology. 2002;143(10):4113-22.

  132. Baserga R, Hongo A, Rubini M, Prisco M, Valentini SB 1997 The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332:F105ā€“F126.

  133. Kulik G, Klippel A, Weber MJ 1997 Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase and Akt. Mol Cell Biol 17:1595ā€“1606.

  134. Chrysis D, Calikoglu AS, Ye P, Dā€™Ercole AJ 2001 Insulin-like growth factor-I overexpression attenuates cerebellar apoptosis by altering the expression of Bcl family proteins in a developmentally specific manner. J Neurosci 21:1481ā€“1489.

  135. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA 1996 Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541ā€“6551.

  136. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME 1997 Regulation of neural survival by the serine-threonine protein kinase Akt. Science 275:661ā€“668.

  137. Mehrhof FB, Muller FU, Bergmann MW, Li P, Wang Y, Schmitz W, Dietz R, von Harsdorf R 2001 In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation 104:2088ā€“2094.

  138. Gleichmann M, Weller M, Schuyltz JB 2000 Insulin-like growth factor-1-mediated protection from neuronal apoptosis is linked to phosphorylation of the pro-apoptotic protein BAD but not to inhibition of cytochrome c translocation in rat cerebellar neurons. Neurosci Lett 282:69ā€“72.

  139. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R 1999 Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19:7203ā€“7215.

  140. Kulik G, Weber MJ 1998 Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 18:6711ā€“6718.

  141. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ 2001 p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98:9666ā€“9670.

  142. Desbois-Moutho C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, Capeau J 2001 Insulin and IGF-1 stimulate the Ī²-catenin pathway through two signalling cascades involving GSK-3Ī² inhibition and Ras activation. Oncogene 20:252ā€“259.

  143. Park BC, Kido Y, Accili D 1999 Differential signaling of insulin and IGF-1 receptors to glycogen synthesis in murine hepatocytes. Biochemistry 38:7517ā€“7523.

  144. Cui H, Meng Y, Bulleit RF 1998 Inhibition of glycogen synthase kinase 3Ī² activity regulates proliferation of cultured cerebellar granule cells. Brain Res Dev Brain Res 111:177ā€“188.

  145. Tamatani M, Ogawa S, NunĢƒez G, Tokyama M 1998 Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death Differ 5:911ā€“919.

  146. Baker NlL, Carlo Russo V, Bernard O, Dā€™Ercole AJ, Werther GA 1999 Interactions between bcl-2 and the IGF-I system control apoptosis in the developing mouse brain. Brain Res Dev Brain Res 118:109ā€“118.

  147. Du K, Montminy M 1998 CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273:32377.

  148. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasly LE, Reusch JE 2000 Akt/protein kinase B upregulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275:10761ā€“10766.

  149. Brod M, Pohlman B, HĆøjbjerre L, Adalsteinsson JE, Rasmussen MH. Impact of adult growth hormone deficiency on daily functioning and well-being. BMC Research Notes. 2014;7:813. doi:10.1186/1756-0500-7-813.

  150. Maggi M, Buvat J, Corona G, Guay A, Torres LO. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med. 2013;10(3):661-77.

  151. Ginzburg E, Lin A, Sigler M, Olsen D, Klimas N, Mintz A. Testosterone and growth hormone normalization: a retrospective study of health outcomes. Journal of multidisciplinary healthcare. 2008;1:79-86.

  152. Brod M, HĆøjbjerre L, Adalsteinsson JE, Rasmussen MH. Assessing the impact of growth hormone deficiency and treatment in adults: development of a new disease-specific measure. J Clin Endocrinol Metab. 2014;99(4):1204-12.

  153. Available at https://www.researchgate.net/publication/12600670_Effects_of_growth_hormone_on_male_reproductive_functions.

  154. Galdiero M, Pivonello R, Grasso LF, Cozzolino A, Colao A. Growth hormone, prolactin, and sexuality. J Endocrinol Invest. 2012;35(8):782-94.

  155. Becker AJ, Uckert S, Stief CG, et al. Possible role of human growth hormone in penile erection. J Urol. 2000;164(6):2138-42.

  156. Becker AJ, Uckert S, Stief CG, et al. Serum levels of human growth hormone during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology. 2002;59(4):609-14.

  157. Otunctemur A, Ozbek E, Sahin S, et al. Low serum insulin-like growth factor-1 in patients with erectile dysfunction. Basic and Clinical Andrology. 2016;26:1. doi:10.1186/s12610-015-0028-x.

  158. Rajfer J. Growth Factors and Gene Therapy for Erectile Dysfunction. Reviews in Urology. 2000;2(1):34.

  159. Pastuszak AW, Liu JS, Vij A. IGF-1 levels are significantly correlated with patient-reported measures of sexual function. International journal of impotence research. 2011; 23(5):220-6.

  160. Pastuszak AW, Liu JS, Vij A, et al. IGF-1 levels are significantly correlated with patient-reported measures of sexual function. Int J Impot Res. 2011;23(5):220-6.

  161. El-Sakka AI, Lin CS, Chui RM, Dahiya R, Lue TF. Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res. 1999;11:123ā€“32. doi: 10.1038/sj.ijir.3900392.

  162. Soh J, Katsuyama M, Ushijima S, Mizutani Y, Kawauchi A, Yabe-Nishimura C, et al. Localization of increased insulin-like growth factor binding protein-3 in diabetic rat penis: Implications for erectile dysfunction. Urology. 2007;70:1019ā€“23. doi: 10.1016/j.urology.2007.07.057.

  163. Pu XY, Zheng XG, Zhang Y, Xiao HJ, Xu ZP, Liu JM, et al. Higher expression of mRNA and protein of insulin-like growth factor binding protein-3 in old rat penile tissues: implications for erectile dysfunction. J Sex Med. 2011;8:2181ā€“90. doi: 10.1111/j.1743-6109.2011.02318.x.

  164. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9.

  165. Rubinek T, Rubinfeld H, Hadani M, Barkai G, Shimon I. Nitric oxide stimulates growth hormone secretion from human fetal pituitaries and cultured pituitary adenomas. Endocrine. 2005;28(2):209-16.

  166. Valverde I, PeƱalva A, Ghigo E, Casanueva FF, Dieguez C. Involvement of nitric oxide in the regulation of growth hormone secretion in dogs. Neuroendocrinology. 2001;74(4):213-9.

  167. Rigamonti AE, Cella SG, Marazzi N, MĆ¼ller EE. Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. Metab Clin Exp. 1999;48(2):176-82.

  168. Doi SQ, Jacot TA, Sellitti DF, et al. Growth hormone increases inducible nitric oxide synthase expression in mesangial cells. J Am Soc Nephrol. 2000;11(8):1419-25.

  169. Available at http://erj.ersjournals.com/content/31/4/815.

  170. Deniz Tuncel, Fatma Inanc Tolun, and Ismail Toru, ā€œSerum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinsonā€™s Disease,ā€ Mediators of Inflammation, vol. 2009, Article ID 132464, 4 pages, 2009.

  171. Available at https://clinicaltrials.gov/ct2/show/NCT00470002.

  172. Bƶger RH , Skamira C , Bode-Bƶger SM , Brabant G , von zur Muhlen A , Frolich JC. 1996. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest 98:2706ā€“2713.

  173. Thum T , Fleissner F , Klink I , Tsikas D , Jakob M , Bauersachs J , Stichtenoth DO. 2007. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab 92:4172ā€“4179.

  174. Mani maran RR, Sivakumar R, Ravisankar B, et al. Growth hormone directly stimulates testosterone and oestradiol secretion by rat Leydig cells in vitro and modulates the effects of LH and T3. Endocr J. 2000;47(2):111-8.

  175. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 1987;64(1):51-8.

  176. Argiolas A, Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol. 2005;76(1):1-21.

  177. Kim KS, Bae WJ, Kim SJ, et al. Improvement of erectile dysfunction by the active pepide from Urechis unicinctus by high temperature/pressure and ultra ā€“ wave assisted lysis in Streptozotocin Induced Diabetic Rats. International Brazilian Journal of Urology: official journal of the Brazilian Society of Urology. 2016;42(4):825-837. doi:10.1590/S1677-5538.IBJU.2015.0606.

  178. Wessells H, Blevins JE, Vanderah TW. Melanocortinergic control of penile erection. Peptides. 2005;26(10):1972-1977. doi:10.1016/j.peptides.2004.11.035.

  179. Melis MR, Argiolas A. Central oxytocinergic neurotransmission: a drug target for the therapy of psychogenic erectile dysfunction. Curr Drug Targets. 2003;4(1):55-66.

  180. Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev. 2011;63(4):811-59.

  181. Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53(3):417-50.

  182. DecaluwƩ K, Pauwels B, Verpoest S, Van de voorde J. New therapeutic targets for the treatment of erectile dysfunction. J Sex Med. 2011;8(12):3271-90.

  183. Ryu B, Kim M, Himaya SWA, Kang KH, Kim SK. Statistical optimization of high temperature/pressure and ultra-wave assisted lysis of Urechis unicinctus for the isolation of active peptide which enhance the erectile function in vitro. Process Biochemistry. 2014;49:148ā€“153.

  184. Liu Q, Jia Z, Duan L, Xiong J, Wang D, Ding Y. Functional peptides for cartilage repair and regeneration. American Journal of Translational Research. 2018;10(2):501-510.

  185. Hastar N, Arslan E, Guler MO, Tekinay AB. Peptide-Based Materials for Cartilage Tissue Regeneration. Adv Exp Med Biol. 2017;1030:155-166.

  186. Wang W, Rigueur D, Lyons KM. TGFbeta signaling in cartilage development and maintenance. Birth Defects Res C Embryo Today. 2014;102:37ā€“51.

  187. Lam HJ, Li S, Lou N, Chu J, Bhatnagar RS. Synthetic peptides cytomodulin-1 (CM-1) and cytomodulin-2 (CM-2) promote collagen synthesis and wound healing in vitro. Conf Proc IEEE Eng Med Biol Soc. 2004;7:5028ā€“5030.

  188. Basu S, Kumar M, Chansuria JP, Singh TB, Bhatnagar R, Shukla VK. Effect of Cytomodulin-10 (TGF-beta1 analogue) on wound healing by primary intention in a murine model. Int J Surg. 2009;7:460ā€“465.

  189. Mittal A, Kumar R, Parsad D, Kumar N. Cytomodulin-functionalized porous PLGA particulate scaffolds respond better to cell migration, actin production and wound healing in rodent model. J Tissue Eng Regen Med. 2014;8:351ā€“36.

  190. Shao Z, Zhang X, Pi Y, Wang X, Jia Z, Zhu J, Dai L, Chen W, Yin L, Chen H, Zhou C, Ao Y. Polycaprolactone electrospun mesh conjugated with an MSC affinity peptide for MSC homing in vivo. Biomaterials. 2012;33:3375ā€“3387.

  191. Huang H, Zhang X, Hu X, Shao Z, Zhu J, Dai L, Man Z, Yuan L, Chen H, Zhou C, Ao Y. A functional biphasic biomaterial homing mesenchymal stem cells for in vivo cartilage regeneration. Biomaterials. 2014;35:9608ā€“9619.

  192. Meng Q, Man Z, Dai L, Huang H, Zhang X, Hu X, Shao Z, Zhu J, Zhang J, Fu X, Duan X, Ao Y. A composite scaffold of MSC affinity peptide-modified demineralized bone matrix particles and chitosan hydrogel for cartilage regeneration. Sci Rep. 2015;5:17802.

  193. Shao Z, Zhang X, Pi Y, Yin L, Li L, Chen H, Zhou C, Ao Y. Surface modification on polycaprolactone electrospun mesh and human decalcified bone scaffold with synovium-derived mesenchymal stem cells-affinity peptide for tissue engineering. J Biomed Mater Res A. 2015;103:318ā€“329.

  194. Webb DJ, Roadcap DW, Dhakephalkar A, Gonias SL. A 16-amino acid peptide from human alpha2-macroglobulin binds transforming growth factor-beta and platelet-derived growth factor-BB. Protein Sci. 2000;9:1986ā€“1992.

  195. Shah RN, Shah NA, Del Rosario Lim MM, Hsieh C, Nuber G, Stupp SI. Supramolecular design of self-assembling nanofibers for cartilage regeneration. Proc Natl Acad Sci U S A. 2010;107:3293ā€“3298.

  196. Chow LW, Armgarth A, St-Pierre JP, Bertazzo S, Gentilini C, Aurisicchio C, McCullen SD, Steele JA, Stevens MM. Peptide-directed spatial organization of biomolecules in dynamic gradient scaffolds. Adv Healthc Mater. 2014;3:1381ā€“1386.

  197. Parmar PA, Chow LW, St-Pierre JP, Horejs CM, Peng YY, Werkmeister JA, Ramshaw JA, Stevens MM. Collagen-mimetic peptide-modifiable hydrogels for articular cartilage regeneration. Biomaterials. 2015;54:213ā€“225.

  198. Recha-Sancho L, Semino CE. Heparin-based self-assembling peptide scaffold reestablish chondrogenic phenotype of expanded de-differentiated human chondrocytes. J Biomed Mater Res A. 2016;104:1694ā€“1706.

  199. Yamaoka H, Asato H, Ogasawara T, Nishizawa S, Takahashi T, Nakatsuka T, Koshima I, Nakamura K, Kawaguchi H, Chung UI, Takato T, Hoshi K. Cartilage tissue engineering using human auricular chondrocytes embedded in different hydrogel materials. J Biomed Mater Res A. 2006;78:1ā€“11.

  200. Kisiday J, Jin M, Kurz B, Hung H, Semino C, Zhang S, Grodzinsky AJ. Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: implications for cartilage tissue repair. Proc Natl Acad Sci U S A. 2002;99:9996ā€“10001.

  201. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986;44:517ā€“518.

  202. Jeschke B, Meyer J, Jonczyk A, Kessler H, Adamietz P, Meenen NM, Kantlehner M, Goepfert C, Nies B. RGD-peptides for tissue engineering of articular cartilage. Biomaterials. 2002;23:3455ā€“3463.

  203. Kim HD, Heo J, Hwang Y, Kwak SY, Park OK, Kim H, Varghese S, Hwang NS. Extracellular-matrix-based and Arg-Gly-Asp-modified photopolymerizing hydrogels for cartilage tissue engineering. Tissue Eng Part A. 2015;21:757ā€“766.

  204. Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. 1995;61(5):584-9.

  205. Moreno-reyes R, Kerkhofs M, Lā€™hermite-balĆ©riaux M, Thorner MO, Van cauter E, Copinschi G. Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. Am J Physiol. 1998;274(5 Pt 1):E779-84.

  206. Frieboes RM, Murck H, Antonijevic IA, Steiger A. Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. J Neuroendocrinol. 1999;11(6):473-8.

  207. Morselli LL, Nedeltcheva A, Leproult R, et al. Impact of growth hormone replacement therapy on sleep in adult patients with growth hormone deficiency of pituitary origin. European journal of endocrinology/European Federation of Endocrine Societies. 2013;168(5):10.1530/EJE-12-1037. doi:10.1530/EJE-12-1037.

  208. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, Lafranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(5):2206-12.

  209. Van cauter E, Copinschi G. Interrelationships between growth hormone and sleep. Growth Horm IGF Res. 2000;10 Suppl B:S57-62.

  210. Copinschi G, Nedeltcheva A, Leproult R, et al. Sleep disturbances, daytime sleepiness, and quality of life in adults with growth hormone deficiency. J Clin Endocrinol Metab. 2010;95(5):2195-202.

  211. Davidson JR, Moldofsky H, Lue FA. Growth hormone and cortisol secretion in relation to sleep and wakefulness. Journal of Psychiatry and Neuroscience. 1991;16(2):96-102.

  212. Moreno-reyes R, Kerkhofs M, Lā€™hermite-balĆ©riaux M, Thorner MO, Van cauter E, Copinschi G. Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. Am J Physiol. 1998;274(5 Pt 1):E779-84.

  213. Shah N, Rice T, Tracy D, et al. Sleep and Insulin-Like Growth Factors in the Cardiovascular Health Study. Journal of Clinical Sleep Medicineā€Æ: JCSMā€Æ: Official Publication of the American Academy of Sleep Medicine. 2013;9(12):1245-1251. doi:10.5664/jcsm.3260.

  214. Mysliwiec V, Gill J, Matsangas P, Baxter T, Barr T, Roth BJ. IGF-1: a potential biomarker for efficacy of sleep improvement with automatic airway pressure therapy for obstructive sleep apnea?. Sleep Breath. 2015;19(4):1221-8.

  215. Izumi S, Ribeiro-filho FF, Carneiro G, Togeiro SM, Tufik S, Zanella MT. IGF-1 Levels are Inversely Associated With Metabolic Syndrome in Obstructive Sleep Apnea. J Clin Sleep Med. 2016;12(4):487-93.

  216. Izumi S, Ribeiro-Filho FF, Carneiro G, Togeiro SM, Tufik S, Zanella MT. IGF-1 Levels are Inversely Associated With Metabolic Syndrome in Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine. 2016;12(4):487-493. doi:10.5664/jcsm.5672.

  217. Rusch HL, Gill JM. Effect of Acute Sleep Disturbance and Recovery on Insulin-Like Growth Factor-1 (IGF-1): Possible Connections and Clinical Implications. Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine. 2015;11(10):1245-1246. doi:10.5664/jcsm.5108.

  218. Prinz PN, Moe KE, Dulberg EM, et al. Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men. J Gerontol A Biol Sci Med Sci. 1995;50(4):M222-6.

  219. Damanti S, Bourron O, Doulazmi M, et al. Relationship between sleep parameters, insulin resistance and age-adjusted insulin like growth factor-1 score in non diabetic older patients. Blondeau B, ed. PLoS ONE. 2017;12(4):e0174876. doi:10.1371/journal.pone.0174876.

  220. ObƔl F, KapƔs L, Gardi J, Taishi P, Bodosi B, Krueger JM. Insulin-like growth factor-1 (IGF-1)-induced inhibition of growth hormone secretion is associated with sleep suppression. Brain Res. 1999;818(2):267-74.

  221. Chennaoui M, Drogou C, Sauvet F, Gomez-merino D, Scofield DE, Nindl BC. Effect of acute sleep deprivation and recovery on Insulin-like Growth Factor-I responses and inflammatory gene expression in healthy men. Eur Cytokine Netw. 2014;25(3):52-7.

  222. Rasmussen MH, WildschiĆødtz G, Juul A, Hilsted J. Polysomnographic sleep, growth hormone insulin-like growth factor-I axis, leptin, and weight loss. Obesity (Silver Spring). 2008;16(7):1516-21.

  223. Levada OA, Troyan AS. Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder. Annals of General Psychiatry. 2017;16:38. doi:10.1186/s12991-017-0161-3.

  224. Peterfi Z, McGinty D, Sarai E, Szymusiak R. Growth hormone-releasing hormone activates sleep regulatory neurons of the rat preoptic hypothalamus. American Journal of Physiology ā€“ Regulatory, Integrative and Comparative Physiology. 2010;298(1):R147-R156. doi:10.1152/ajpregu.00494.2009.

Other Peptides

Epithalon

BPC-157

MK-677 (IBUTAMOREN)

Argireline + Leuphasyl

PE-22-28

Success Stories

men testimonial before after

At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions Iā€™ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old Movie Director (ā€œThe Notebookā€, ā€œJohn Qā€, ā€œAlpha Dogā€), Actor and Writer

See All Menā€™s Testimonials

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:
  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have

About

GenemedicsĀ® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.

Quick Links

Our Services

Ā Our Locations

genemedics logo

280 North Old Woodward Ave. Suite 210 Birmingham MI 48009,USA

800-277-4041

info@genemedics.com

© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.

Back to Top
-

Free Consultation

STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:

  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have
Captch Background